Comparison of Adjuvant Chemotherapy With or Without Endocrine Therapy in High-Risk, Node Negative Breast Cancer Patients, and a Natural History Follow-up Study in Low-Risk Node Negative Patients (to initially low risk patients)
Publication Information Expand/Collapse
PMid: PMID29370458 | PMC number: PMC5963502
Survival by Hispanic Ethnicity Among Cancer Patients participating in SWOG Clinical Trials
PMid: PMID27986655 | PMC number: PMC5370550
PMid: PMID28586789; PMC5710507
Association between BMI at treatment initiation and cancer survival across multiple SWOG trials
Gene polymorphisms in cyclophosphamide metabolism pathway, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer [PMC3058716; PMID21169260]
Manganese superoxide dismutase polymorphism treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer [PMID 20309628; PMC2968705]
Treatment quality and outcomes of African American versus Caucasian breast cancer patients: retrospective analysis of Southwest Oncology Group studies S8814-S8897 [PMC2674002; PMID19307504]
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for breast cancer: results from an ancillary study to Southwest Oncology Group Trial S8897 (INT-0102). [PMC2799053;PMID19752340]
Nitric oxide synthase (N0S3) variants and breast cancer survival in a cooperative group trial (SWOG S8897) [PMC2745926; PMID19671875]
Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group (SWOG) protocol S8897 [PMID 18227530]
The Southwest Oncology Group: progress in cancer research [PMID18929152]
Pharmacogenetics and breast cancer treatment outcomes: results on oxidative stress-related genotypes (MPO, MnSOD) from a Southwest Oncology Group intergroup trial (INT-0102)
Outcome of African American women with breast cancer in cooperative group clinical trials
Treatment quality and outcome of African American vs. European American breast cancer patients: retrospective analysis of southwest oncology group studies S8814/S8897
Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup protocol INT-0102
Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer.
Adjuvant therapy for very young women with breast cancer: need to tailored treatments
CMF versus CAF with or without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: Update of tamoxifen results
CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of intergroup trial INT 0102.
A study of the late cardiac effects of two different adjuvant chemotherapy regimens in women with node negative breast cancer treated on SWOG 8897.
Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: An analysis of two intergroup studies.
The influence of patient characteristics, socioeconomic (SES) factors, geography, and systemic risk on the use of breast sparing treatment in adjvant breast cancer studies.